Key Highlights
- ADMA Biologics (NASDAQ:ADMA) was quoted 23.09% higher at USD 12.90 in premarket trading on November 5, 2026, after third-quarter Net Income of USD 49.9 million.
- Evommune (NYSE:EVMN) was quoted 19.70% higher at USD 7.23, with USD 288.0 million of cash at June 30, 2026.
- Ocugen (NASDAQ:OCGN) was quoted 9.78% higher at USD 0.96, with topline data for OCU400 expected in the first quarter of 2027.
- NervGen Pharma (NASDAQ:NGEN) was quoted 7.41% higher at USD 1.45. CalciMedica (NASDAQ:CALC) was quoted 9.67% higher at USD 1.48 with a cash runway guided into the fourth quarter of 2026.
ADMA Biologics (NASDAQ:ADMA): The Only Profit Engine in the Group
ADMA Biologics (NASDAQ:ADMA) reported third-quarter 2026 results on November 4, 2026, and the shares were quoted 23.09% higher at USD 12.90 in premarket trading on November 5, 2026, per the premarket quote. Revenue was USD 141.1 million, up 5.1%, and GAAP net income was USD 49.9 million, or USD 0.22 per diluted share. The headline growth hides a shift in mix: ASCENIV revenue rose 30.7% to USD 124.7 million, while BIVIGAM fell 35.2% to USD 15.4 million and intermediates dropped to USD 0.9 million from USD 15.0 million. ASCENIV carries higher margins, so Gross Profit reached USD 99.9 million, a gross Margin of 71% against 56%. Adjusted EBITDA was USD 77.3 million. Full-year guidance now calls for at least USD 530 million of revenue, at least USD 180 million of adjusted net income and at least USD 275 million of adjusted EBITDA. Cash was USD 124.6 million against long-term Debt of USD 191.6 million, and 16.5 million shares were repurchased year to date. The BIVIGAM decline and the chance that a premarket jump fades are the main risks.
Ocugen (NASDAQ:OCGN): Pipeline Dates Against Going-Concern Doubt
Ocugen (NASDAQ:OCGN) published its third quarter 2026 Business update and quarterly report, with the filing date inferred as November 4, 2026, and the shares were quoted 9.78% higher at USD 0.96 in premarket trading on November 5, 2026, per the premarket quote. The net loss narrowed to USD 3.6 million from USD 20.1 million, helped by a USD 16.6 million non-cash derivative gain. Without it the loss would have been about USD 20.2 million, simple arithmetic on two published numbers. Cash, restricted cash and short-term investments were USD 84.6 million. The pipeline sets the story: OCU400 for retinitis pigmentosa has completed enrollment of 140 patients, with topline data in the first quarter of 2027 and a biologics license application in the second quarter of 2027. The quarterly filing states substantial doubt about the company's ability to continue as a Going Concern within one year. With 339.3 million shares outstanding, the premarket quote implies a Market Value near USD 326 million, simple arithmetic. Shares below USD 1.00 can swing on a small number of trades, and further financing could dilute holders.
NervGen Pharma (NASDAQ:NGEN): Phase 3 Funded, but the Quote Sits Below the Offering Price
NervGen Pharma (NASDAQ:NGEN), a clinical-stage company developing NVG-291 for spinal cord injury, was quoted 7.41% higher at USD 1.45 in premarket trading on November 5, 2026, per the premarket quote. No same-day catalyst was found, and the latest filed update reviewed is the second-quarter 2026 report of August 13, 2026. The FDA aligned on the design of the Phase 3 RESTORE trial in April 2026, with topline data expected in the first half of 2028. Cash was CAD 86.8 million, or USD 61.1 million, after a USD 60.0 million offering at USD 2.50 per unit on May 22, 2026, with each unit carrying a Warrant at USD 3.68. The second-quarter net loss of CAD 29.2 million included a CAD 19.4 million non-cash warrant loss, which rises when the share price rises. The quote is well below the USD 2.50 offering price. A USD 50.0 million at-the-market Facility set up on July 2, 2026 can add shares and dilute holders. A partial clinical hold on NVG-291 is disclosed in the management discussion, and Phase 3 trials can Fail even after encouraging early data.
Evommune (NYSE:EVMN): Large Cash Cushion, Binary Readouts
Evommune (NYSE:EVMN) was quoted 19.70% higher at USD 7.23 in premarket trading on November 5, 2026, per the premarket quote, with no same-day catalyst verified. The latest verified financial update is the second-quarter 2026 report issued on August 6, 2026. Cash, cash equivalents and investments were USD 288.0 million at June 30, 2026, with a runway guided through 2028. The quarterly net loss was USD 32.2 million against USD 13.6 million as Research and Development spending rose to USD 26.4 million, and no revenue was recorded. The pipeline is centred on EVO756, an oral drug: a Phase 2b trial in chronic spontaneous urticaria missed its primary endpoint at all doses in June 2026 and that indication was discontinued. A Phase 2b migraine prevention trial of about 330 patients began in July 2026, with topline data expected in 2027. A September 2026 atopic dermatitis announcement exists, but its figures were not verified here. Clinical-stage biotechs trade on binary outcomes, so each readout can move the stock sharply in either direction, and a premarket quote can reverse.
CalciMedica (NASDAQ:CALC): Reverse Split and a Short Runway
CalciMedica (NASDAQ:CALC) was quoted 9.67% higher at USD 1.48 in premarket trading on November 5, 2026, per the premarket quote. Its most recent major corporate action is a one-for-five Reverse Stock Split announced on August 27, 2026, which raises the quoted price without changing the value of a holder's stake. The latest financials are from the first quarter of 2026, reported on May 12, 2026: net income of USD 5.0 million came from a USD 10.8 million non-cash Fair Value change, while operating expenses were USD 5.6 million. Cash was USD 8.2 million with a runway guided into the fourth quarter of 2026, which implies more Capital is needed and Equity raises dilute holders. In the CARPO Phase 2b trial in acute pancreatitis, the high-dose arm showed a stratified win ratio of 1.640. The company awaits FDA feedback on a possible pivotal program. The KOURAGE kidney injury trial was paused in January 2026 after a monitoring committee flagged a mortality imbalance. As a micro-cap, a small number of trades can move the price and quoted moves can reverse.
Where Things Stand
The biotech and pharma group spans one profitable company and four names whose quotes depend on trial timelines and funding, so the evidence favors treating the moves as early trading, not conviction. ADMA Biologics (NASDAQ:ADMA) has filed profit and a raised outlook. Evommune (NYSE:EVMN) has cash into 2028 but binary readouts. Ocugen (NASDAQ:OCGN) has pipeline dates and going-concern doubt. NervGen Pharma (NASDAQ:NGEN) is funded for Phase 3 yet quoted below its offering price. CalciMedica (NASDAQ:CALC) has a runway only into the fourth quarter of 2026. Each premarket quote can reverse.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...